Benefits of Victoza (liraglutide) in type 2 diabetes during fasting- Novo Nordisk

New findings showed that adults with type 2 diabetes treated with Victoza (liraglutide), from Novo Nordisk, in combination with metformin, experienced similar improvements in blood glucose control while fasting during Ramadan (four weeks) compared with sulfonylurea (SU) plus metformin. During Ramadan, patients treated with Victoza experienced fewer confirmed hypoglycaemic episodes compared with people treated with sulfonylurea (2.0% vs. 4.3%), even though the Victoza group had lower fructosamine concentration at the start of Ramadan. In addition, greater weight loss was observed in people treated with Victoza during Ramadan vs. sulfonylurea (-1.43 kg vs. -0.89 kg).

In the LIRA-Ramadan study, people treated with Victoza from baseline to the end of Ramadan were more likely to achieve an HbA1c target of <7% with no confirmed hypoglycaemic episodes compared with sulfonylurea 53.9 vs. 23.5. also people treated with victoza compared with sulfonylurea experienced significantly greater weight loss -5.40 kg vs. -1.46 kg had significantly greater improvements in hba1c -1.24 vs. -0.65 were more likely to achieve the target level of hba1c><7% 57.1 vs. 26.4 and experienced significant reductions in fructosamine levels -39.6 mol l vs. -29.3 mol l. findings from the lira-ramadan study were presented at the 75th annual scientific sessions of the american diabetes association.>